Navigation Links
Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
Date:12/13/2011

izartinib in 7-day cycles between chemotherapy, and continuous dosing of quizartinib layered on top of chemotherapy.  Effect of the different treatments was measured by effects on tumor growth delay, tumor burden, tumor regression levels over time.

The results of these preclinical studies demonstrated that both low and high doses of quizartinib can be safely combined with the Ara-C + DNR chemotherapy regimen, and that there was no antagonism between the treatments, regardless of schedule or dose.  Dosing quizartinib in combination with Ara-C, or in combination with Ara-C + DNR, resulted in improved effect on tumor burden, tumor growth delay and tumor regression versus dosing either agent or regimen alone.  Continuous dosing of quizartinib layered on top of chemotherapy produced the best results.  In Study 3, the combination of continuous quizartinib and Ara-C + DNR lead to rapid and complete regression which was sustained for a longer period of time versus any other treatment arm.  For episodic dosing, high dose quizartinib post Ara-C had improved results compared to initiating quizartinib post DNR.  Supported by these findings, a Phase 1 clinical study has recently been initiated to evaluate the combination of quizartinib and standard induction and consolidation chemotherapy in newly diagnosed AML patients.

About Quizartinib

Quizartinib, formerly known as AC220, is being developed in collaboration between Ambit Biosciences and Astellas Pharma Inc. and is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor.  Quizartinib is currently under evaluation in a Phase 2 clinical trial as monotherapy treatment for adult and elderly patients with relapsed/refractory AML that have an internal tandem duplication (ITD) mutation in the FLT3 gene.

About Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a form of blood cancer. 
'/>"/>

SOURCE Ambit Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
2. Ambit Biosciences Announces Transition in Company Leadership
3. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
4. Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
5. Astellas Awards Educational Scholarships to Six Transplant Recipients Who Embody the Spirit of Giving Back
6. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
7. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
8. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
9. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
10. CV Therapeutics Statement on Unsolicited Proposal From Astellas
11. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Topical BioMedics, Inc., is celebrating 20 ... their suffering, restoring hope an quality of life and ... possible because of the innovative cellular biomedicines research that ... reality. , The company was founded in 1994 ... (president, chief of research, and Topricin inventor), Aurora Paradise ...
(Date:9/22/2014)... Pa. (PRWEB) September 22, 2014 ... rapid diagnostics for the food and beverage industries, ... will be distributed under a non-exclusive agreement by ... and services. , Enartis, an Esseco Group company ... to winemakers in California and other global markets ...
(Date:9/22/2014)... N.J. , Sept. 22, 2014  WIRB-Copernicus ... and ethical review services for clinical research, announced ... (WIRB) has been reaccredited by the Association ... (AAHRPP), which endeavors to improve safeguards for clinical ... Donald A. Deieso , Ph.D., commented, "It ...
(Date:9/22/2014)... BETHESDA, Md. , Sept. 22, 2014  Spherix Incorporated ... fostering and monetization of intellectual property, today announced that the ... patent to the Company in the month of September that ... The issued patent is: USRE45,121 , ... 2014 , Filing date: Dec 27, 2012 ...
Breaking Biology Technology:Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3Western IRB (WIRB) Awarded AAHRPP Reaccreditation 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3
... Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS;, ... next,generation of monoclonal antibodies based on its Dynamic ... and Chairman, will,present at the 7th Annual BIO ... Morhet,s thirty-minute presentation to potential investors and,industry partners ...
... Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET), NOVATO, Calif., Oct. 28 , ... Q3 2008 ... 190.5% increase Naglazyme Net Product Revenue ... Aldurazyme Net Sales by Genzyme $38.2 ...
... ASA (OSL:DIAG),today announced that it has signed ... panEuropean provider of gene expression-based,diagnostic testing and ... marking scheduled in early2009, DiaGenic will be ... Europe its innovative blood-based,gene-expression diagnostic test for ...
Cached Biology Technology:InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum 2BioMarin Announces Third Quarter 2008 Financial Results 2BioMarin Announces Third Quarter 2008 Financial Results 3BioMarin Announces Third Quarter 2008 Financial Results 4BioMarin Announces Third Quarter 2008 Financial Results 5BioMarin Announces Third Quarter 2008 Financial Results 6BioMarin Announces Third Quarter 2008 Financial Results 7BioMarin Announces Third Quarter 2008 Financial Results 8BioMarin Announces Third Quarter 2008 Financial Results 9BioMarin Announces Third Quarter 2008 Financial Results 10BioMarin Announces Third Quarter 2008 Financial Results 11BioMarin Announces Third Quarter 2008 Financial Results 12Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests 2
(Date:9/22/2014)... In 2011 the Society of Environmental Toxicology and ... to identify and prioritize the scientific research needed to ... (PPCPs) in the environment. The effort was extended, ... of the Society,s international journal, Integrated Environmental Assessment ... accompanied by a podcast interviewing the lead author of ...
(Date:9/22/2014)... 22, 2014)The Brain & Behavior Research Foundation ... NARSAD Young Investigator Grants valued at more ... world,s most promising young scientists. Recipients of ... research will seek to identify causes, improve ... disorders that affect one in four people, ...
(Date:9/22/2014)... 22, 2014) Additive manufacturing (AM), or 3D ... production of complex-shaped metal components strong enough for ... errors and distortions, as well as quality standards ... pace with the technology. Engineers at the University ... to develop enhanced modeling and simulation (M&S) technology ...
Breaking Biology News(10 mins):Priorities for research on pharmaceutical and personal care products in the environment 2Brain & Behavior Research Foundation awards 200 NARSAD Young Investigator grants 2Pitt engineers receive grants to enhance additive manufacturing 2Pitt engineers receive grants to enhance additive manufacturing 3
... 30, 2013 /PRNewswire-iReach/ -- Clinilabs, a contract research organization ... to industry, announced today that they have begun a ... for Type 2 Diabetes Mellitus.  The study is being ... daily doses of the investigational medication over periods of ...
... the University of Wisconsin-Madison have made a discovery that, ... may contribute to diseases like Alzheimer,s and Parkinson,s, which ... the brain. With proteins, shape is everything. The ... molecules about a cell, others to provide essential cellular ...
... laboratory work allowed a diverse team of University of Pittsburgh ... Nature Cell Biology that they had solved the mystery ... By discovering a mechanism by which mitochondria tiny structures ... they are damaged and need to be eliminated, the Pitt ...
Cached Biology News:Leading Pharma Company Selects Clinilabs to Conduct a Phase 1 Study of an Investigational Type 2 Diabetes Medication 2Zinc, proteins, and an essential cellular balancing act 2When cells 'eat' their own power plants; Pitt scientists solve mystery of cellular process 2When cells 'eat' their own power plants; Pitt scientists solve mystery of cellular process 3
... The FastPlax Antibody is used to detect ... the surface of infected cells as early ... basis of the FastPlax Titer Kit, which ... 25-48 hours. The FastPlax Antibody ...
Alexa Fluor 647 anti-mouse IL-12 (Interleukin-12) / IL-23 (Interleukin-23) p40 25 ug...
PKC (pSer345), phospho-specific...
PE Rat anti-Hu CD267 Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: